EndoDNA Awarded Landmark U.S. Patent for Machine-Learning Genetic and Biometric Efficacy Platform

LOS ANGELES - May 30, 2025 - PRLog -- EndoDNA, Inc., a pioneer in precision health technology, is proud to announce the issuance of U.S. Patent No. 12,288,603 B2 by the United States Patent and Trademark Office (USPTO). The patent, titled "Machine-Learning Based Efficacy Predictions Based on Genetic and Biometric Information," protects EndoDNA's proprietary system for generating personalized therapeutic recommendations based on an individual's DNA, biometric data, and machine learning models.

This innovation marks a critical milestone in the evolution of precision health and wellness science, allowing for the optimization of treatment outcomes using a person's unique biological signature as well as biomarkers to established personalized treatment plans and create a one-of-a-kind decision support platform for healthcare professionals. The patent was granted on April 29, 2025, to inventors Len May and Eric Kaufman.

"This patent represents more than just technology—it's the foundation of a healthcare revolution," said Len May, CEO and Co-Founder of EndoDNA. "By integrating DNA, Epigenetics, biomarkers, biometric inputs, and AI, we're empowering individuals and practitioners to make smarter, safer, and more effective decisions about their treatment protocols and the best part is that the AI is always learning to make even better personalized outcome recommendations."

A Game-Changer for Precision Wellness

The patented method enables:

• Collection and analysis of genetic and biometric data from multiple individuals
• Application of machine learning algorithms to determine the most effective intervention protocol
• Real-time generation of individualized therapeutic protocols that are scientifically grounded and dynamically adaptable

The system is already being used to power EndoDNA's personalized MyDNA Co-Pilot ™ platform, which has served over 8,000 users globally and is rapidly expanding into functional medicine, hormone therapy, and mental wellness markets.

Broad Implications for Healthcare

EndoDNA's platform uniquely positions it at the intersection of biotech, digital health, and personalized therapeutics. The newly patented methodology applies to any therapeutic compound or supplement where genetic and metabolic individuality plays a role in efficacy.

With this intellectual property, EndoDNA is advancing its mission to close the gap between genetic potential and health optimization, offering tools that help clinicians and consumers alike "decode their DNA" and "encode their wellness."

About EndoDNA

EndoDNA, Inc. is a biotech company transforming personal health through DNA-based insights and machine learning. With a mission to personalize wellness, the company delivers actionable recommendations via its EndoDNA testing platform, now enhanced by its newly patented platform. EndoDNA is trusted by medical professionals, wellness clinics, and forward-thinking consumers around the world.

For more information, visit: https://www.endodna.com

Media Contact:
Len@endodna.com
(833) 363-6226